Recessive X Chromosome Disorders – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Recessive X Chromosome Disorders – Drugs In Development, 2023’, provides an overview of the Recessive X Chromosome Disorders pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Recessive X Chromosome Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Recessive X Chromosome Disorders and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Recessive X Chromosome Disorders
- The report reviews pipeline therapeutics for Recessive X Chromosome Disorders by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Recessive X Chromosome Disorders therapeutics and enlists all their major and minor projects
- The report assesses Recessive X Chromosome Disorders therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Recessive X Chromosome Disorders
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Recessive X Chromosome Disorders
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Recessive X Chromosome Disorders pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AAVogen IncADEL Inc
Allagium therapeutics Inc
Alpha Anomeric
American CryoStem Corp
AMO Pharma Ltd
Anagenesis Biotechnologies SAS
Antisense Therapeutics Ltd
ARMGO Pharma Inc
ART BioScience
Astria Therapeutics Inc
AUM LifeTech Inc
Autotac Bio Inc
Avidity Biosciences Inc
Axolo Pharma Inc
BioIncept LLC
Bioleaders Corp
BioMarin Pharmaceutical Inc
Biophytis SA
CANbridge Life Sciences Ltd
Capricor Therapeutics Inc
ChemIcare Srl
Chengdu Fanxi Biopharma Co Ltd
Chengdu Genevector Biotechnology Co Ltd
Code Biotherapeutics Inc
Consortium.AI
Constant Therapeutics LLC
Cumberland Pharmaceuticals Inc
Curamys Co Ltd
Cure Rare Disease
Daiichi Sankyo Co Ltd
DR.Noah Biotech Inc
Dyne Therapeutics Inc
Dystrogen Therapeutics SA
ECM Therapeutics Inc
Edgewise Therapeutics Inc
Editas Medicine Inc
Eli Lilly and Co
Eloxx Pharmaceuticals Inc
Encell Co Ltd
Entrada Therapeutics Inc
Epirium Bio Inc
EspeRare Foundation
FibroGenesis LLC
Fulcrum Therapeutics Inc
Genethon SA
Harvard University
hC Bioscience Inc
HuidaGene Therapeutics Co Ltd
ImmunoForge Co Ltd
Imstem Biotechnology Inc
Inmune Bio Inc
InnoBioscience LLC
Insmed Inc
Intas Pharmaceuticals Ltd
IPS Heart Inc
Italfarmaco SpA
Ixchel Pharma LLC
J2H Biotech
JAR of Hope
Juvena Therapeutics Inc
Kaneka Corp
Keros Therapeutics Inc
Korea Pharma Co Ltd
Korea University
KSbitugen Co Ltd
LambdaGen Therapeutics
Les Laboratoires Servier SAS
Locanabio Inc
Ludi Therapeutics
MetrioPharm AG
Mitobridge Inc
Mitochon Pharmaceuticals Inc
MitoRx Therapeutics Ltd
MyoGene Bio LLC
Myogenica Inc
Myos Inc
Myosana Therapeutics Inc
Nippon Shinyaku Co Ltd
Northwestern University
Novo Biosciences Inc
NS Pharma Inc
NTrans Technologies BV
OliPass Corporation
OMEICOS Therapeutics GmbH
Oncotelic Therapeutics Inc
Orna Therapeutics Inc
Pepgen Inc
PeptiDream Inc
Perelman School of Medicine at the University of Pennsylvania
Pfizer Inc
Pliant Therapeutics Inc
Prime Medicine Inc
Progenitor Therapeutics Ltd
Prothelia Inc
PTC Therapeutics Inc
PYC Therapeutics Ltd
Quince Therapeutics Inc
Ractigen Therapeutics Inc
RASRx LLC
RegenxBio Inc
ReoStem LLC
ReveraGen BioPharma Inc
Ridgeline Therapeutics LLC
Royal Holloway University of London
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Sarepta Therapeutics Inc
Satellos Bioscience Inc
SiVEC Biotechnologies LLC
Solid Biosciences Inc
SOM Biotech SL
Sqy Therapeutics SA
Stanford University
Stealth BioTherapeutics Inc.
Stem Cells of Arabia
SteroTherapeutics LLC
Strykagen Corp
Sutura Therapeutics Ltd
Suzhou GenAssist Therapeutics Co Ltd
Taiho Pharmaceutical Co Ltd
Technical University of Munich
Tevard Biosciences LLC
The Hospital for Sick Children
Tivorsan Pharmaceuticals Inc
Tolerion Inc
Triplex Therapeutics Inc
UGISense AG
Ultragenyx Pharmaceutical Inc
University Children's Hospital Basel
University of Alberta
University of California Los Angeles
University of Exeter
University of Montreal
University of Pennsylvania
University of Queensland
University of Wisconsin Madison
Vertex Pharmaceuticals Inc
Vita Therapeutics Inc
Vitti Labs LLC
Wave Life Sciences Ltd
Zata Pharmaceuticals Inc